The American College of Cardiology, the American Heart Association, and the Heart Failure Society of America published the guidelines in various journals April 1. The new guidelines revise original stages of heart failure, from A-D, to identify heart failure risk factors early. The treatment strategies for symptomatic patients were updated to include SGLT-2 inhibitor medications.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
